Atlantic Union Bankshares Corp Sells 1,655 Shares of Abrdn Life Sciences Investors (NYSE:HQL)

Atlantic Union Bankshares Corp decreased its position in Abrdn Life Sciences Investors (NYSE:HQL) by 6.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 24,148 shares of the company’s stock after selling 1,655 shares during the quarter. Atlantic Union Bankshares Corp’s holdings in Abrdn Life Sciences Investors were worth $317,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of HQL. Penserra Capital Management LLC bought a new position in Abrdn Life Sciences Investors in the 3rd quarter worth about $11,702,000. Absolute Investment Advisers LLC bought a new position in Abrdn Life Sciences Investors in the 4th quarter worth about $5,242,000. Raymond James Financial Inc. bought a new position in Abrdn Life Sciences Investors in the 4th quarter worth about $3,129,000. Wolverine Asset Management LLC bought a new position in Abrdn Life Sciences Investors in the 4th quarter worth about $1,594,000. Finally, Kingswood Wealth Advisors LLC bought a new position in Abrdn Life Sciences Investors in the 4th quarter worth about $160,000. Institutional investors own 32.21% of the company’s stock.

Insider Buying and Selling at Abrdn Life Sciences Investors

In other Abrdn Life Sciences Investors news, major shareholder Saba Capital Management, L.P. sold 15,143 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $14.27, for a total transaction of $216,090.61. Following the transaction, the insider now owns 3,381,371 shares in the company, valued at approximately $48,252,164.17. This represents a 0.45 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have sold 108,386 shares of company stock worth $1,511,590. Company insiders own 10.06% of the company’s stock.

Abrdn Life Sciences Investors Trading Up 0.6 %

Shares of Abrdn Life Sciences Investors stock opened at $13.22 on Friday. The firm’s 50-day moving average is $13.69 and its 200 day moving average is $14.34. Abrdn Life Sciences Investors has a 1 year low of $12.76 and a 1 year high of $15.90.

Abrdn Life Sciences Investors Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Friday, February 21st will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 14.23%. The ex-dividend date is Friday, February 21st.

Abrdn Life Sciences Investors Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.